Strata Oncology scores $26 million for large-scale next-generation sequencing
The company plans to bring NGS to health systems lacking the ability to perform it internally.
The company plans to bring NGS to health systems lacking the ability to perform it internally.
Next-generation sequencing firm plans to present data on its gargantuan genomics study at ASCO next month.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
After decades of research and theoretical debates, it seems precision oncology is finally falling into place, capped off with Thursday's approval of a companion diagnostic for multiple cancer therapies.
The king of life science acquisitions has struck again. Thermo Fisher Scientific has announced plans to acquire Patheon, a Durham, North Carolina-based contract development and manufacturing organization with 9,000 employees worldwide.
Thermo Fisher's universal companion diagnostic is nearing approval for NSCLC with the support of multiple pharma partners. The panel is designed to screen 47 genes with one small DNA input.
The new company, called Origin Technologies, are making this play about a week before Affymetrix shareholders plan to vote on the Thermo Fisher deal. The new bid will offer shareholders $16.10 per share in cash, up from Thermo Fisher's offer of $14 per share, as the New York Times points out.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.